Abstract: Patients with breast cancer carrying BRCA1/2 germline pathogenic mutations have a unique pathogenesis and clinicopathological characteristics, with potentially different clinical management, when compared to patients with sporadic breast cancers. A growing number of BRCA1/2-mutated breast cancers have been detected with the development of next-generation sequencing, which has led to an increasing interest in clinical management of these patients. In this review, we summarize recent studies on genetic testing and systematic treatment, including surgery, chemotherapy, and targeted therapy, to assist in treatment decisions for BRCA1/2-mutated breast cancers.